Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Camlin Fine Sciences's Total Liabilities for the quarter that ended in Mar. 2026 was ₹13,231 Mil. Camlin Fine Sciences's Total Assets for the quarter that ended in Mar. 2026 was ₹23,239 Mil.
Therefore, Camlin Fine Sciences's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2026 was 0.57.
Camlin Fine Sciences (NSE:CAMLINFINE) Liabilities-to-Assets Explanation
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Camlin Fine Sciences Liabilities-to-Assets Related Terms
Camlin Fine Sciences Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for Camlin Fine Sciences's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:CAMLINFINE vs LIN, SHW, ECL: Liabilities-to-Assets Comparison
For the Specialty Chemicals subindustry, Camlin Fine Sciences's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camlin Fine Sciences Liabilities-to-Assets vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Camlin Fine Sciences's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Camlin Fine Sciences's Liabilities-to-Assets falls into.
Camlin Fine Sciences Liabilities-to-Assets Calculation
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Camlin Fine Sciences's Liabilities-to-Assets Ratio for the fiscal year that ended in Mar. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Camlin Fine Sciences (NSE:CAMLINFINE) has a Liabilities-to-Assets of 0.57 as of Mar. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Camlin Fine Sciences and its competitors.
Is Camlin Fine Sciences' Liabilities-to-Assets too high?
Camlin Fine Sciences' current Liabilities-to-Assets is 0.57. Overall, Camlin Fine Sciences has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camlin Fine Sciences' Liabilities-to-Assets compare to LIN and SHW?
Camlin Fine Sciences' Liabilities-to-Assets of 0.57 can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Chemicals company?
A good Liabilities-to-Assets depends on the Chemicals industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Camlin Fine Sciences and its competitors. Camlin Fine Sciences's current Liabilities-to-Assets is 0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camlin Fine Sciences stock overvalued right now?
Based on GuruFocus' analysis, Camlin Fine Sciences (NSE:CAMLINFINE) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹143.87, compared to a current price of ₹127.74 — trading 11.2% below its estimated fair value. The current Liabilities-to-Assets is 0.57. Camlin Fine Sciences' overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Camlin Fine Sciences (NSE:CAMLINFINE), the current Liabilities-to-Assets is 0.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camlin Fine Sciences (NSE:CAMLINFINE) Overvalued in 2026?
Based on GuruFocus' analysis, Camlin Fine Sciences stock appears to be undervalued.
The current stock price of ₹127.74 is trading 11.2% below its estimated GF Value™ of ₹143.87.
GuruFocus considers Camlin Fine Sciences to be Modestly Undervalued.
Key valuation signals for NSE:CAMLINFINE:
Liabilities-to-Assets: 0.57
GF Value™: ₹143.87 vs. price of ₹127.74 (11.2% below fair value)
No single metric tells the full story. See the NSE:CAMLINFINE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camlin Fine Sciences Ltd is engaged in research, development, manufacturing, commercializing, and marketing of specialty chemicals and blends. These chemicals are used in food, feed, animal and pet nutrition and industrial products. The Company has only one reportable segment, namely, Speciality Chemicals. The company's product portfolio consists of Shelf life solutions, Aroma ingredients, Performance chemicals and Health & Wellness. Shelf life extension solutions include antioxidant solutions which are used to increase the shelf life of oils and. Aroma vertical includes a production of Vanillin and Ethyl Vanillin. Performance Chemicals consist of Guaiacol, Veratrole, TBC, and MEHQ and are used in sectors such as food flavoring, pharmaceuticals intermediate fragrance industry.
62GF Score
Get the complete analysis for NSE:CAMLINFINE
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CAMLINFINE has been successfully added to your 
